Showing posts with label safe medicines. Show all posts
Showing posts with label safe medicines. Show all posts

Thursday, February 27, 2020

A Secure Drug Supply Chain is the Best Anti-Counterfeiting Technology We Have

By: Shabbir J. Safdar, Executive Director, The Partnership for Safe Medicines

There are several technologies that have been developed to identify and weed out counterfeit medicines, from serialization to edible security tags on individual pills, but no anti-counterfeiting technology can take the place of a secure, and well-enforced medication supply chain.

Serialization, a central part of our Track & Trace system, provides unique identifying tags on individual packages of medication at the point of manufacture. It is an effective means of quickly spotting fake medicine. However, if you allow members into your supply chain that aren’t effectively regulated, or that are sloppy, it will not prevent patient harm. Though it will make it easier to find the problem after the fact in a follow up investigation by checking the serial numbers against numbers from the manufacturer.

One of PSM’s board members is fond of saying that no technology can protect you when someone is intent on trading your safety to make a dollar. Missing holograms can be ignored, serialized product can be mixed or repackaged with non-serialized product, and other means of making more money and endangering the patient. Serialization will always find the problem after the fact, but our safety goal is higher: we want to prevent such products from ever reaching patients in the first place.

Edible tags, such as the one’s being developed at Purdue University can make identifying genuine pills easier, but again, vigilance on the part of supply chain members is key to their success. A patient may be very interested indeed to find out if their prescribed medication is genuine but if their doctor does not bother to check, the security of edible tags is pointless.

Patients seldom see the packaging of injectable medications such as Avastin, used in cancer treatment; Prolia and Aclasta, used to treat osteoporosis; and Botox, used in treatments ranging from cosmetic to dental and ocular. Every one of these injectable treatments has been counterfeited and successfully sold in the United States, because no one bothered to the genuineness of the medication by examining the packages or checking lot and serial numbers or they had a financial incentive not to. In the case of counterfeit Avastin, U.S. authorities only discovered that American doctors were treating their patients with it when the United Kingdom’s MHRA alerted the FDA in 2012 to warn them that a fake version was in circulation.

If members of the secure supply chain do not carefully examine medication packaging and pills to verify that they genuine using anti-counterfeiting technology, drug counterfeiters can easily fool them with similar packaging and identical-looking pills and vials. The visual spotting of a fake by its label, box, or pill shape and color is imperfect, at best.

Real and counterfeit Alli pictures
Real and counterfeit Alli pictures

Lastly, there has been a lot of press about using blockchain technology to keep counterfeit drugs out of the supply chain. Manufacturers can use technological tracking of their products throughout the supply chain, but if any member of the supply chain ignores digital footprints for medication or fails to recognize their lack, blockchain falls apart and does nothing to protect patients. The best technology to protect patients from counterfeit medication is strong regulation, a secure supply chain, and clear consequences for manufacturers, wholesalers, distributors, and medical professionals who ignore or sidestep the supply chain. In every case where counterfeit medicine has reached patients, bad actors consciously breaking the supply chain put fake drugs in the hands of doctors, clinics, and pharmacies..

References:
  • Lilly Serialization: https://www.lilly.com/products/anti-counterfeiting/serialization
  • TC Medical: https://www.safemedicines.org/2015/05/canada-based-company-that-acted-as-drop-shipper-pays-33-million-fine-in-misbranded-drug-smuggling-case.html
  • Securing Industry edible tags: https://www.securingindustry.com/pharmaceuticals/purdue-scientists-detail-edible-security-tags-for-medicines/s40/a11237/#.XjryFC2ZO9
  • Black Market Cancer: https://www.safemedicines.org/2018/08/imported-black-market-cancer-meds.html
  • Black Market Osteoporosis: https://www.safemedicines.org/2013/01/the-us-food-and-drug-administrationfda-has-issued-warning-letters-to-20-us-doctors-that-they.html
  • Black Market Botox: https://www.safemedicines.org/2014/10/black-market-injectable-cosmetic-treatments-a-nationwide-problem-10-22-14.html
  • PSM Fake Avastin: https://www.safemedicines.org/2012/02/mhra-fda-cooperation-rousts-counterfeit-cancer-drugs.html
  • Reuters Blockchain: https://www.insurancejournal.com/news/national/2020/02/21/559057.htm
Disclaimer: Guest blogs do not necessarily reflect the views of the ADAP Advocacy Association, but rather they provide a neutral platform whereby the author serves to promote open, honest discussion about public health-related issues and updates.

Thursday, June 27, 2019

HIV/AIDS Fireside Chat Retreat in Michigan Tackles Pressing Issues

By: Brandon M. Macsata, CEO, ADAP Advocacy Association

The ADAP Advocacy Association hosted an HIV/AIDS "Fireside Chat" retreat in Detroit, Michigan among key stakeholder groups to discuss pertinent issues facing people living with HIV/AIDS. The Fireside Chat took place on Thursday, June 20th, and Friday, June 21st. Safe Medicines, HIV Criminalization, and the Ryan White HIV/AIDS Program ("RWHAP") were dissected by 24 diverse leaders in the fight against the HIV/AIDS epidemic.

FDR Fireside Chat
Photo Source: Getty Images

The Fireside Chat included moderated white-board style discussion sessions on the following issues:
  • Safe Medicines: Combatting the Dangerous Foothold Counterfeit Medicines Have Gained in the U.S.moderated by Shabbir Safdar
  • HIV Criminalization: Ending the Stigmatization of the HIV/AIDS Epidemic, moderated by Robert Suttle
  • Ryan White Program: Impact to Service Delivery under Trump’s Plan to Eliminate AIDS by 2030, moderated by Jeffrey S. Crowley
The discussion sessions were designed to capture key observations, suggestions, and thoughts about how best to address the challenges being discussed at the Fireside Chat. The following represents the attendees:
  • Khadijah I. Abdullah, Founder & Executive Director, RAHMA & National Faith HIV/AIDS Awareness Day
  • Marjorie Ambrosio-Whitson, Vice President of Clinical Operations, ScriptGuideRx
  • Guy Anthony, President & CEO, Black, Gifted & Whole Foundation
  • William E. Arnold, President & CEO, Community Access National Network (CANN)
  • Olivier Bahizi, Advocate
  • Hala Bazzi-Lang, PharmD. RMGO, Local Specialty Registered Store Manager, Walgreens
  • Elmer Cerano, Retired & Board Member, ADAP Advocacy Association
  • Noel Chavez-Guizar, Clinic Case Manager, Rocky Mountain CARES
  • Tori Cooper, Founder & Executive Director, Advocates for Better Care Atlanta
  • Jeffrey S. Crowley, Distinguished Scholar & Program Director at the Infectious Disease Initiatives, O'Neill Institute for National and Global Health Law, Georgetown Law
  • Chris E. Davis, Attorney, Michigan Protection & Advocacy Service (MPAS)
  • Terry-Ann Francis, MPH, Global Professional Relations & Independent Medical Education, Global Medical Affairs, Merck
  • Stephen Hourahan, Consultant 
  • Lisa Irwin, Senior Manager, Project & Program Management, MagellanRx
  • Brandon M. Macsata, CEO, ADAP Advocacy Association
  • Stephen Novis, Government Relations Director, ViiV Healthcare
  • Murray C. Penner, Executive Director – North America, Prevention Access Campaign - U=U
  • Ioana Popa-Simil, Advocate
  • Alan Richardson, Executive Vice President of Strategic Patient Solutions, Patient Advocate Foundation
  • Josh Robbins, Owner, BNA Talent Group & The BRANDagement
  • Shabbir Imber Safdar, Executive Director, Partnership for Safe Medicines
  • Robert Skinner, President & CEO, Valley AIDS Information Network
  • Robert Suttle, Assistant Director, SERO Project 
  • Ian Wendt, Executive Director, HIV Community Operations, Gilead Sciences
The ADAP Advocacy Association is pleased to share the following brief recap of the Fireside Chat.

Safe Medicines:

According to Shabbir Safdar, 2019 has been an interesting year legislatively for the issue of pharmaceutical supply chain safety. Bills to attempt to legislate Canadian drug importation have been proposed in Utah, Colorado, Oregon, Missouri, Florida, Connecticut, and Maine. Bills have passed state legislatures in Colorado and Florida. These proposals attempt to create a pipeline of excess medicine, not needed by the Canadian population, to American patients.

One key question asked was can this work or are these bills actually implementable?
Prior experiments were reviewed, including: What has been the experience of other states that have implemented importation? Did it get used? Does it save money? What has changed about the market since the last programs in 2000-2010?
  • Illinois’ iSaveRX: Safety issues, missing inspections, terminated with low utilization
  • MN RXConnect: Safety issues, terminated with low utilization
  • Maine: No inspections, confirmed counterfeit, overturned in Federal court
  • Vermont: Not implemented yet, better savings through Medicaid, Projected savings to insurance companies: $2.61 to $2.82 per member, per month.
Questions over the politics of importation included: What has the rhetoric around these bills been like? Are state legislatures considering safety when passing them? Does spending time or money on legislation like this defer other priorities? Is this more of a soundbite than a real proposal?

During the meeting, some examples were shared of where a patient dollar for a pharmaceutical goes.  An infographic shows the complexity of how money flows in the U.S. healthcare supply chain.

The following materials were shared with retreat attendees:
The ADAP Advocacy Association would like to publicly acknowledge and thank Shabbir for facilitating this important discussion.

HIV Criminalization:

According to some estimates, 14% (or 1 in 7) of all people living with HIV (PLHIV) in the United States, and 20% (1in 5) of Black Americans living with HIV, will pass through a jail or prison every year. Though there is variation state to state, the prevalence of HIV in state and federal prisons in the United States is nearly five times greater than that of the general population.  The factors associated with disproportionate rates of incarceration -- such as drug use, non-conforming sexual and gender identity, mental illness, poverty, or being a person of color – can also augment a person’s risk of contracting HIV. Further, over 30 states have laws in place that criminalize alleged HIV exposure, non-disclosure, or transmission. Many states also apply harsher penalties to sex workers and people who inject drugs on the basis of HIV status. These laws perpetuate stigma of criminality, undercut public health, and disproportionately affect women, people of color, and other marginalized communities.

Photo Source: Queerty.com
Efforts to reform HIV criminal laws are underway across the U.S. In the last year alone, reform was proposed or achieved in several states. The experiences in these states offer numerous lessons:
  • Public health buy-in can be critical for success
  • The need to draw connection between different advocacy communities, including those focused on HIV, LGBTQ+ rights, mass incarceration, sex workers’ rights and harm reduction. 
  • In state legislatures education is critical and support can come from unexpected places. 
While HIV criminal laws must be reformed to address the overrepresentation of PLHIV in the criminal legal system, it is also essential to consider broader drivers of incarceration of PLHIV, including the war on drugs and discrimination against people of color and LGBTQ+ people in housing, employment, and education. Mass incarceration and HIV are linked epidemics, and the systemic injustices that drive mass incarceration also power the continued transmission and increasing prevalence of HIV in marginalized communities. Advocacy efforts, which seek to reform HIV criminal laws without attention to broader community-level factors impacting risk of incarceration for PLHIV are incomplete.

The following materials were shared with retreat attendees:
The ADAP Advocacy Association would like to publicly acknowledge and thank Robert for facilitating this important discussion.

Ryan White Program:

The Ryan White HIV/AIDS Program was discussed, as well as the potential intersection with the Administration's plan to End the Epidemic by 2030 (EtE) initiative. As a foundational point for this discussion, some important facts were shared on why is the Ryan White Program needed if people with HIV have health insurance coverage, especially its role in leading the way in getting people with HIV virally suppressed by ensuring stable access to HIV primary care and medication, along with critical support services.

The discussion included a summary on the progression from 2010 National HIV/AIDS Strategy to 2015 Strategy to Trump Administration plans. Additionally, it reviewed what is the role of the Ryan White Program and HRSA/HAB leadership in this initiative, as well as what are the opportunities and challenges with this effort?

Ending the Epidemic
Photo Source: HIV.gov

There was considerable debate on where the HIV community stands on the EtE initiative, which led to a broader conversation whether it is possible to define the "community" since there are often significant disconnects between national, state, and grassroots opinions.

With ongoing concerns over the current Administration, Ryan White reauthorization was weighed in the context of the current political environment. Yet there was recognition that the program would need to be updated at some point in time. That discussion led to a broader conversation on how is the program addressing emerging or other issues (Rapid Start of ART, HCV Elimination, Opioid/SUD response, STIs, other issues).

The following materials were shared with retreat attendees:
The ADAP Advocacy Association would like to publicly acknowledge and thank Jeffrey for facilitating this important discussion.

Additional 2019 Fireside Chats are planned in Richmond, Virginia, and New York, New York.


Thursday, January 17, 2019

Safe Medicines in the United States aren't a Guarantee

By: Brandon M. Macsata, CEO, ADAP Advocacy Association

In 2019, prescriptions medicines in the United States are not immune from the increasing dangers associated with counterfeit drugs. In fact, it can be a serious issue. Dating back to the start of the HIV/AIDS epidemic in the United States, it is an issue that has also resulted in Black Market HIV/AIDS prescription medicines falling into the unknowing hands of HIV-positive consumers. Therefore, raising awareness about counterfeit drugs and the dangers associated with drug importation is an issue the ADAP Advocacy Association takes very seriously.

On January 31st, we are proud to sponsor a series of Congressional Briefings on counterfeit medications  which are being hosted by The Partnership for Safe Medicines ("PSM"). It is an issue that has impacted me, personally, and why I penned an Op-Ed in the Washington Blade last year on the inherent dangers (Drug importation policy is a hard pill to swallow).

I ordered medications from an online Canadian pharmacy. To this day, I have no way of knowing where the drugs were made or if they contained the active ingredients I needed to effectively treat my condition.

Counterfeit medications affect all patients: patients with acute diagnoses, patients with chronic conditions, and patients with immunodeficiency. A patient who has an acute bacterial infection needs a legitimate antibiotic with a proper dose to kill the bacteria and is endangered by the rebounding infection caused by a counterfeit that is beneath sufficient dosage. A patient with a chronic condition who needs maintenance medications may weaken and worsen if their maintenance meds are substandard in dosage. Patients with immunodeficiency may end up with serious additional infections if medications they take have not been sourced and stored in sterile conditions.

HIV patients may suffer all of these things at the hands of unscrupulous drug counterfeiters. Come to PSM's Congressional Briefings to hear the stories of counterfeit medicine victims, including an HIV patient, who received counterfeit drugs that impacted his health. Upcoming legislation proposals to bypass the U.S. Food and Drug Administration's safety protocols and import medicine from foreign sources that can neither be verified nor regulated will have profound affect upon all of the populations of patients who depend upon safe, accurate medicine to maintain their health.

HIV red ribbon next to spoon filled with Rx medicines
Photo Source: Community Access National Network

Black Market HIV/AIDS prescription drugs have been in the news for many years. In fact, several years ago PSM published an important report in collaboration with the Community Access National Network ("CANN"). The PSM-CANN report outlined numerous instances of counterfeit drugs in the HIV/AIDS drug supply change between 2006 and 2013. Download the report online.

Register today to attend either the free House breakfast event at 9 a.m., or the free Senate lunch event at 12 p.m., on January 31, 2019 in Washington, DC.